Pay in 4 interest-free payments of $5.72 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
In preclinical characterization studies (Coskun et al., 2022, Molecular Metabolism), retatrutide demonstrated potent agonist activity at all three target receptors: GIP receptor : High-potency agonism derived from the GIP backbone scaffold
261 : 418429 Shen S, Strobel HW
phase 2 trial data confirm gastrointestinal side effects are common, though heartburn was not consistently itemised as a standalone adverse event
Retatrutide is designed to activate three hormone receptor pathways involved in appetite, glucose handling, and energy balance
US$ 28.42
US$ 22.66
US$ 20.58
